Metadata record for the manuscript: RIPK1 is a negative mediator in Aquaporin 1-driven triple-negative breast carcinoma progression and metastasis

<b>Summary</b>

This
metadata record provides details of the data supporting the claims of the
related manuscript: “RIPK1 is a negative mediator in
Aquaporin 1-driven triple-negative breast carcinoma progression and metastasis”.

The
related study reports the aberrant expression of Aquaporin 1 (AQP1) and
receptor-interacting protein kinase 1 (RIPK1) in triple-negative breast
carcinoma (TNBC) that are associated with different prognoses, then validates
the interaction of AQP1 and RIPK1 and the suppressive effect of RIPK1 on
AQP1-driven TNBC progression and metastasis, and finally identifies the
underlying mechanism of TNBC cell death resistance that AQP1 binds to the D324
site of RIPK1 and facilitates RIPK1 cleavage by promoting the caspase-8/RIPK1
negative feedback loop.

Type of data:
mass spectrometry

Subject of
data: <i>Homo sapiens</i>; Eukaryotic cell
lines; <i>Mus musculus</i>

Population
characteristics: human patients were female, diagnosed with TNBC and average
age 45.4 years; seven-week-old female BALB/c mice

Recruitment:
consecutively recruited between May 1, 2012 and April 30, 2013 at Tianjin
Medical University Cancer Institute and Hospital and the First Affiliated
Hospital of Xiamen University

<b>Data
access</b>

The public
data resources used in the related study are openly available from the
following sources: the Oncomine database (http://www.oncomine.org),
the Cancer Genome Atlas (TCGA, https://identifiers.org/cbioportal:brca_tcga),
Genotype-Tissue Expression (GTEx, https://gtexportal.org),
and the Gene Expression Omnibus data repository (GEO, https://identifiers.org/geo:GSE1456,
https://identifiers.org/geo:GSE6532,
and https://identifiers.org/geo:GSE7390).

The majority
of the GraphPad Prism files underlying the figures and supplementary figures of
the related article are openly available as part of this data record. However,
several are saved in institutional storage and are not publicly available to
protect the patient privacy. These may be available from the corresponding author
upon reasonable request.

All the
uncropped western blots generated during this study are available in
Supplementary Figure 6.<br>

<b>Corresponding author(s) for this study</b>

Fanxin
Zeng, Ph.D., Department of Clinical Research Center, Dazhou Central Hospital, No.56
Nanyuemiao St, Tongchuan District, Dazhou, 635000, China, Phone: +86-
818-2381051, E-mail: [e-mail].

Huiwen
Ren, Ph.D., Department of Pharmacology, School of Basic Medical Sciences, Tianjin
Medical University, No.22 Qixiangtai Rd. Heping District, Tianjin, 300070,
China, Phone: [phone], E-mail: [e-mail].

<br>
<b>Study approval </b>

The
study conformed to the Ethical Guidelines of the Helsinki Declaration, and was
approved by the Ethics Committee of Tianjin Medical University Cancer Institute
and Hospital, Tianjin, and the Ethics Committee of the First Affiliated
Hospital of Xiamen University, Xiamen, People’s Republic of China.